Cargando…
Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9
[Image: see text] Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670427/ https://www.ncbi.nlm.nih.gov/pubmed/23641937 http://dx.doi.org/10.1021/ja402016p |
_version_ | 1782271843206430720 |
---|---|
author | Lonsdale, Richard Houghton, Kerensa T. Żurek, Jolanta Bathelt, Christine M. Foloppe, Nicolas de Groot, Marcel J. Harvey, Jeremy N. Mulholland, Adrian J. |
author_facet | Lonsdale, Richard Houghton, Kerensa T. Żurek, Jolanta Bathelt, Christine M. Foloppe, Nicolas de Groot, Marcel J. Harvey, Jeremy N. Mulholland, Adrian J. |
author_sort | Lonsdale, Richard |
collection | PubMed |
description | [Image: see text] Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the reaction mechanisms and have the potential to make predictions of metabolite formation. Here we present a comprehensive study of the oxidation of three widely used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-metabolizing P450 isoforms, CYP2C9. The reaction barriers to substrate oxidation by the iron-oxo species (Compound I) have been calculated at the B3LYP-D/CHARMM27 level for different possible metabolism sites for each drug, on multiple pathways. In the cases of ibuprofen and warfarin, the process with the lowest activation energy is consistent with the experimentally preferred metabolite. For diclofenac, the pathway leading to the experimentally observed metabolite is not the one with the lowest activation energy. This apparent inconsistency with experiment might be explained by the two very different binding modes involved in oxidation at the two competing positions. The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 side chain in the transition state for formation of the observed metabolite—but not in that for the competing pathway. We compare reaction barriers calculated both in the presence and in the absence of the protein and observe a marked improvement in selectivity prediction ability upon inclusion of the protein for all of the substrates studied. The barriers calculated with the protein are generally higher than those calculated in the gas phase. This suggests that active-site residues surrounding the substrate play an important role in controlling selectivity in CYP2C9. The results show that inclusion of sampling (particularly) and dispersion effects is important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods. |
format | Online Article Text |
id | pubmed-3670427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-36704272013-06-03 Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 Lonsdale, Richard Houghton, Kerensa T. Żurek, Jolanta Bathelt, Christine M. Foloppe, Nicolas de Groot, Marcel J. Harvey, Jeremy N. Mulholland, Adrian J. J Am Chem Soc [Image: see text] Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the reaction mechanisms and have the potential to make predictions of metabolite formation. Here we present a comprehensive study of the oxidation of three widely used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-metabolizing P450 isoforms, CYP2C9. The reaction barriers to substrate oxidation by the iron-oxo species (Compound I) have been calculated at the B3LYP-D/CHARMM27 level for different possible metabolism sites for each drug, on multiple pathways. In the cases of ibuprofen and warfarin, the process with the lowest activation energy is consistent with the experimentally preferred metabolite. For diclofenac, the pathway leading to the experimentally observed metabolite is not the one with the lowest activation energy. This apparent inconsistency with experiment might be explained by the two very different binding modes involved in oxidation at the two competing positions. The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 side chain in the transition state for formation of the observed metabolite—but not in that for the competing pathway. We compare reaction barriers calculated both in the presence and in the absence of the protein and observe a marked improvement in selectivity prediction ability upon inclusion of the protein for all of the substrates studied. The barriers calculated with the protein are generally higher than those calculated in the gas phase. This suggests that active-site residues surrounding the substrate play an important role in controlling selectivity in CYP2C9. The results show that inclusion of sampling (particularly) and dispersion effects is important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods. American Chemical Society 2013-05-03 2013-05-29 /pmc/articles/PMC3670427/ /pubmed/23641937 http://dx.doi.org/10.1021/ja402016p Text en Copyright © 2013 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) |
spellingShingle | Lonsdale, Richard Houghton, Kerensa T. Żurek, Jolanta Bathelt, Christine M. Foloppe, Nicolas de Groot, Marcel J. Harvey, Jeremy N. Mulholland, Adrian J. Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title | Quantum Mechanics/Molecular Mechanics Modeling of
Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title_full | Quantum Mechanics/Molecular Mechanics Modeling of
Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title_fullStr | Quantum Mechanics/Molecular Mechanics Modeling of
Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title_full_unstemmed | Quantum Mechanics/Molecular Mechanics Modeling of
Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title_short | Quantum Mechanics/Molecular Mechanics Modeling of
Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 |
title_sort | quantum mechanics/molecular mechanics modeling of
regioselectivity of drug metabolism in cytochrome p450 2c9 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670427/ https://www.ncbi.nlm.nih.gov/pubmed/23641937 http://dx.doi.org/10.1021/ja402016p |
work_keys_str_mv | AT lonsdalerichard quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT houghtonkerensat quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT zurekjolanta quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT batheltchristinem quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT foloppenicolas quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT degrootmarcelj quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT harveyjeremyn quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 AT mulhollandadrianj quantummechanicsmolecularmechanicsmodelingofregioselectivityofdrugmetabolismincytochromep4502c9 |